CVRx Reports Q1 2025 Revenue Growth, Expands Active Implanting Centers

CVRx, Inc. reported a 15% increase in total revenue to $12.3 million in Q1 2025, driven by U.S. heart failure market growth. The company expanded its active implanting centers to 227, a 19% increase from the previous year. Gross profit rose to $10.3 million, while the net loss narrowed to $13.8 million. CVRx expects continued revenue growth and aims to enhance Barostim's market penetration with its expanded sales force and clinical evidence.

Minneapolis, May 11, 2025 — CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, has reported its financial and operating results for the first quarter of 2025. The company reported total revenue of $12.3 million, representing a 15% increase over the prior year quarter [1].

The growth was primarily driven by the U.S. heart failure (HF) market, which contributed $11.1 million in revenue, a 14% increase from the same period last year [1]. This expansion was facilitated by the addition of new sales territories and increased physician and patient awareness of Barostim, the company's implantable neuromodulation device [1].

CVRx also reported a 19% increase in the number of active implanting centers in the U.S., reaching 227 as of March 31, 2025 [1]. This growth is indicative of the company's successful market penetration and the growing acceptance of Barostim as a treatment option for heart failure patients.

The company's gross profit for the quarter was $10.3 million, up 13% from the prior year [1]. This improvement was partially offset by a net loss of $13.8 million, a significant reduction from the $22.2 million net loss reported in the same period last year [1]. The narrowing of the net loss can be attributed to the company's operational efficiencies and strategic cost reductions.

CVRx expects continued revenue growth for the full year of 2025, projecting total revenue between $55.0 million and $58.0 million [1]. The company aims to enhance Barostim's market penetration by leveraging its expanded sales force and growing body of clinical evidence, which has demonstrated significant reductions in hospital visits for patients treated with Barostim [1].

The company will host a conference call to review its results on May 8, 2025, at 4:30 p.m. Eastern Time. For more information, visit the investor relations page on the company's website at ir.cvrx.com [1].

References:
[1] https://www.biospace.com/press-releases/cvrx-reports-first-quarter-2025-financial-and-operating-results